Torren Management’s Beta Bionics BBNX Stock Holding History

Torren Management’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-82	Closed	-$822	–	985
2026 Q1	$822	Sell	82 -54	-40%	-$799	﹤0.01%	779
2025 Q4	$4.14K	Buy	+136	New	+$3.63K	﹤0.01%	943

Other funds holding BBNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Evanson Financial Mclean, Virginia $2.04B AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return

Torren Management's BBNX Position: Q2 2026 in Review

Torren Management sold out of Beta Bionics (BBNX) in Q2 2026, closing a stake of 82 shares — an estimated $822 sold.

Torren Management first reported a position in BBNX in Q4 2025 and held it in 2 quarters. The position peaked at $4.14K in Q4 2025. 43 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

Torren Management reported no remaining Beta Bionics position as of Q2 2026 after selling out during the quarter.
Torren Management sold 82 Beta Bionics shares in Q2 2026, an estimated $822.
Torren Management first reported a position in Beta Bionics in Q4 2025 and held it in 2 quarters.
Torren Management's Beta Bionics position peaked at $4.14K in Q4 2025.
43 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.